K M Seng

TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore.

TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore.